US 12,285,538 B2
Embolic compositions and methods
Jeffrey Groom, Belmont, MA (US); Craig Wiltsey, Waltham, MA (US); Quynh Pham, Methuen, MA (US); Nikhita Mansukhani, Allston, MA (US); Courtney Guertin, Watertown, MA (US); Lee Core, Needham, MA (US); and Upma Sharma, Somerville, MA (US)
Assigned to Arsenal Medical, Inc., Waltham, MA (US)
Filed by Arsenal Medical, Inc., Waltham, MA (US)
Filed on Jun. 27, 2024, as Appl. No. 18/756,729.
Application 18/756,729 is a continuation of application No. 18/502,937, filed on Nov. 6, 2023, granted, now 12,053,560.
Application 18/502,937 is a continuation of application No. 18/322,852, filed on May 24, 2023, granted, now 11,844,870, issued on Dec. 19, 2023.
Application 18/322,852 is a continuation of application No. 18/001,024, previously published as PCT/US2021/036636, filed on Jun. 9, 2021.
Claims priority of provisional application 63/036,564, filed on Jun. 9, 2020.
Prior Publication US 2024/0350701 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 24/06 (2006.01); A61K 47/02 (2006.01); A61K 47/34 (2017.01); A61K 49/04 (2006.01); A61L 24/00 (2006.01); A61L 24/02 (2006.01); A61L 24/04 (2006.01); C08L 83/04 (2006.01)
CPC A61L 24/06 (2013.01) [A61K 47/02 (2013.01); A61K 47/34 (2013.01); A61K 49/04 (2013.01); A61K 49/0409 (2013.01); A61L 24/0021 (2013.01); A61L 24/02 (2013.01); A61L 24/043 (2013.01); A61L 24/046 (2013.01); C08L 83/04 (2013.01); A61L 2400/06 (2013.01); A61L 2430/36 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method comprising: (a) forming a crosslinkable composition for vascular embolization comprising:
(i) providing a first suspension comprising (A) a crosslinkable polymer and (B) a first imaging agent having an average primary particle size from 80 nm to 200 nm;
(ii) providing a second suspension comprising (A) a crosslinker and, optionally, (B) a second imaging agent having an average primary particle size from 80 nm to 200 nm; and
(iii) mixing the first suspension and the second suspension with a dry composition, the dry composition comprising a first silica filler and, optionally, a second silica filler that is the same or different from the first silica filler;
thereby forming the crosslinkable composition, wherein the first imaging agent, the second imaging agent, the first silica filler, and the optional second silica filler are dispersed in the crosslinkable composition;
(b) preparing the crosslinkable composition for injection; and
(c) injecting the crosslinkable composition into an injection site within a vasculature of a patient whereupon the crosslinkable composition substantially flows into and occludes a target vessel in the vasculature, and whereafter the crosslinkable composition crosslinks and forms into a solid.